pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ALKSAlkermes plc.

$ALKS48.02-4.30%
Dublin 4, IEupdated 4h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
1
phase 3
1
catalysts ytd
3
approvals ytd
1
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 1Phase 3: 1Marketed: 1Unknown: 2
1Phase 11Phase 31Marketed2Unknown
Marketed
(olanzapine + samidorphan l-malate)
Bipolar Disorder (Manic Depression)
Phase 3
alixorexton
Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Phase 1
valiloxybate ER
Narcolepsy
drug
LYBALVI
1 INDICATIONS AND USAGE LYBALVI is indicated for the trea…
D2-like dopamine receptor5-hydroxytryptamine receptor 2C
drug
VIVITROL
1 INDICATIONS AND USAGE Treatment with VIVITROL should be…
Opioid receptors; mu/kappa/delta

📅 Upcoming

Oct 28, 2026
earnings
$ALKS48.02-4.30%
in 2mo
Alkermes plc. earnings
Alkermes plc.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 6, 26SELLGaffin David Joseph· EVP, CLO, Alkermes, Inc.2,034 sh @ $34.57−$70K↗
  • Apr 1, 26SELLHopkinson Craig C.· EVP R&D, Chief Medical Officer9,000 sh @ $35.51−$320K↗
  • Mar 3, 26SELLGaffin David Joseph· EVP, CLO, Alkermes, Inc.2,034 sh @ $29.76−$61K↗
  • Mar 2, 26SELLHopkinson Craig C.· EVP R&D, Chief Medical Officer9,000 sh @ $29.72−$267K↗
  • Mar 2, 26SELLParisi Samuel Joseph· VP, Finance (Interim PAO)6,890 sh @ $29.29−$202K↗
  • Mar 2, 26SELLNichols Christian Todd· SVP, Chief Commercial Officer6,000 sh @ $30.00−$180K↗
  • Mar 2, 26SELLGaffin David Joseph· EVP, CLO, Alkermes, Inc.2,034 sh @ $29.29−$60K↗
routine RSU / option mechanics (6)
  • Apr 11, 26tax coverLurker Nancy · director901 sh
  • Apr 11, 26option exerciseLurker Nancy · director3,751 sh
  • Apr 11, 26option exerciseLurker Nancy · director3,751 sh
  • Apr 1, 26option exerciseHopkinson Craig C. · EVP R&D, Chief Medical Officer5,000 sh
  • Apr 1, 26option exerciseHopkinson Craig C. · EVP R&D, Chief Medical Officer5,000 sh
  • Mar 2, 26option exerciseHopkinson Craig C. · EVP R&D, Chief Medical Officer5,000 sh
🐶 Hiring Signal
next earnings Oct 28, 2026
No open roles indexed yet — view Alkermes plc. jobs →

News

  • 4 potential biotech M&A targets, plus a pretty sure bet from J&J
    Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
    biospace · 15d ago
identifiers
ticker
$ALKS
SEC CIK
0001520262
country
IE
source
sec_tickers
top tags
Schizophrenia1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 35m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?